Radboudumc as business partner. Presentation by Dirkjan Masman (Director Valorisation) during 'From Molecule to Business' event by SMB Life Sciences and Health Valley at NovioTechCampus, Nijmegen, The Netherlands on September 29, 2016.

1. SMB, Nijmegen
29 september 2016
Radboudumc als businesspartner

2. Dirkjan Masman
From public to private to technology transfer
2013 Valorization Radboudumc
2011 Radboud Translational Research BV (Cyclotron on Radboud Campus)
2007 Business Generator Groningen (RUG & UMC Groningen)
2005 Angteq BV (UMC Groningen)
2003 Aesculaap BV (Utrecht University)
1996 Leadd BV (Leiden University)
1991 Institute for Veterinarian Research BV (Wageningen University)
1988 Groningen University, Postdoc
1986 University of Washington, Seattle, USA, Research fellow
1982 Groningen University, PhD

3. To take home
• Medisch onderzoek is gericht op “unmet medical needs”
• Innovaties komen bij patiënt via commercialisatie
• Publiek-Private Consortia zijn onontbeerlijk
• Radboudumc is “dus” ook een zakenpartner

4. Radboud Campus Nijmegen
Radboud Campus Nijmegen
Total employees: 5.050
Academic staff: 2.914
Annual turnover: € 542 million
Students: 18.891
Scientific publications: 6.716
PhD Theses: 384
Total employees: 11.000
Annual turnover: € 1 billion
Beds: 1000
Medical specialists: 587
Students: 3.300
Professors: 147
Scientific publications: 3.396
PhD theses: 186

5. Patient
Radboud
Personalized Healthcare
A significant impact
on healthcare
Molecule
Population
5

6. Research themes and institutes
6www.radboudumc.nl/Research/Themes/Pages/default.aspx
NWO 10 juni 2016: Spinozapremie voor onderzoek naar afweersysteem

11. Valorisation Department (20 fte)
• Business Development
Spin-offs, licenses, patents
• Legal Affairs
MTA, NDA, CTA
• Subsidies & Finance
Horizon2020, ERC, NWO, EFRO
• (Project) Support
• Direct report to Board of Directors
• Strong support Holding Company

12. Professionals
Publications
Shareholder
License
Contract Research
Joint Research
Impact of Radboudumc

13. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Investeringsrisico
Impactonhealthcare
Radboudumc beleid ‘van idee tot spin-off’

14. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Investeringsrisico
Impactonhealthcare
CHECK door
Octrooifonds
• Onderzoek financiering
• 1e, 2e & 3e geldstroom
Radboud
Innovatie Fonds
SUPPORT door
Subsidies,
non-diluting cash
Radboudumc beleid ‘van idee tot spin-off’

15. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Investeringsrisico
Impactonhealthcare
CHECK door
Seed
Late stage
VC’s
& banks
Thuja
Capital &
PPM oost
Octrooifonds
• Onderzoek financiering
• 1e, 2e & 3e geldstroom
Radboud
Innovatie Fonds
SUPPORT door
Subsidies,
non-diluting cash
Radboudumc Holding B.V.
Pre-Seed
Radboudumc beleid ‘van idee tot spin-off’

16. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Investeringsrisico
Impactonhealthcare
CHECK door
Seed
Late stage
VC’s
& banks
Thuja
Capital &
PPM oost
Octrooifonds
• Onderzoek financiering
• 1e, 2e & 3e geldstroom
Radboud
Innovatie Fonds
SUPPORT door
Subsidies,
non-diluting cash
Radboudumc Holding B.V.
Pre-Seed
Radboudumc beleid ‘van idee tot spin-off’

17. LS&H portfolio Radboud Holding BV
Year Spin-off’s
founded
1996 1
2006 1
2007 1
2008 1
2009 1
2011 2
2012 3
2013 1
2014 4
2015 4
• Holding founded in 2007
• 19 companies (founded and aquired)
• 153 fte
• € 44 million invested

18. Founded 11-11-2014
Product:
MedValue helps medical technology companies to extend their market opportunities, reduce
the(financial) risks and to improve their impact and profit. MedValue provides options (report) to
optimize the added value of innovations for patients and other stakeholders.
Via Medvalue 4 “state of the art” Radboudumc operation rooms will be prepared, fully equipped with
intra-operative imaging (CT, MRI, Echography), in vivo microscopy, intra-operative radiotherapy en
intra-operative navigation.
These facilities are also accessible for companies for testing, trials en training sessions.
CEO: Richard van den Broek
Headcount: 7
www.medvalue.nl

19. CEO: Juliëtte van den Dolder
Headcount: 1
Stem cell researchers need 3D
scaffolds to mimic human nature.
Batch variation, animal origin, cell
recovery are drawbacks of current 3D
scaffolds.
Noviocell´s technology is poly
isocyanopeptide (PIC) hydrogel.
PIC hydrogel is:
• reproducible
• synthetic
• ease of cell recovery
• performs uniquely like collagen
• allows for modularity and
tailoring of scaffold properties
Noviocell develops a 3D solution
for stem cell researchers
3D human organs2D cell culture ware
Tubular structures of Huvec cells
in PIC hydrogel with RGD
peptide, VEGF and FGF
PIC hydrogel performs uniquely like
collagen
Founded 12-11-2015

20. Binnenkort
Meniscus prothese Multimodal imaging New Statines

21. To take home
• Medisch onderzoek is gericht op “unmet medical needs”
• Innovaties komen bij patiënt via commercialisatie
• Publiek-Private Consortia zijn onontbeerlijk
• Radboudumc is “dus” ook een zakenpartner

22. Dirkjan Masman (PhD)
Director Knowledge and Technology Transfer Office
Radboud University Medical Center
Reinier Postlaan 2, HP903
6525 GC Nijmegen
The Netherlands
Dirkjan.masman@radboudumc.nl
Office +31(0)24 3651500
Mob.+31 (0)6 222 473 56

23. Founded in 2006
Exit September 2015, still on Campus
Product:
a molecular diagnostic research and
service company providing an expert-
based, integrated approach in
developing advanced and clinically useful
molecular diagnostic assays for the
uro-oncological practice.
MDx Health
CEO: J. Groen, PhD
COO: Chr. Thibodeau
Advisors Dr. Willem Melchers and
Prof. Dr. Jack Schalken, RUMC

24. Legal entity founded: March 2007
Operational start: November 2012
Products:
Pre-clinical and clinical drug candidates for
mitochondrial disease
www.khondrion.com
CEO: Prof. dr. Jan Smeitink
Headcount: 12
www.khondrion.com

25. Founded 18-8-2011
Product:
RTM b.v. has been established with the objective of creating a fully equipped cyclotron facility.
In this facility we aim to manufacture a range of GMP compliant, routine and experimental
radiopharmaceuticals for our internal customers (research institutes of the Radboudumc) as
well as for external clients.
CEO: Frans Pieters
Headcount: 10
www.radboudtranslationalmedicine.nl

26. Founded 2-8-2012
Activity:
discovery and development of drugs
against malaria.
CEO: dr. Koen Dechering
Headcount: 8
www.tropIQ.nl

27. Founded 8-10-2012
Product:
Development, production and sales of medical devices and instruments - specifically in
the field of Magnetic Resonance Imaging (MRI) and MR-guided interventions.
CEO: Jan Sabisch
CTO: Gerrit Tigelaar
Headcount: 3
www.soteria-medical.com

28. Founded 9-10-2013
Product:
life-prolonging therapeutics for advanced
prostate cancer. A central process for an
incipient cancer cell to become invasive is epithelial-to-
mesenchymal transition (EMT). Oncodrone’s proprietary
drug candidate
(OCD155) reverses the EMT, thereby
destroying the cancer.
CEO: Henk Viëtor
CSO: Jack Schalken
Headcount: 4
www.oncodrone.com

29. Founded 28-2-2014
Product:
Development of computer algorithms for analyzing medical imaging data. Thirona current
focus is on quantitative computed tomography analysis for obstructive lung diseases.
www.thirona.com
CEO: Eva van Rikxoort
CSO: Bram van Ginneken
Headcount: 13
www.thirona.eu

30. Founded 8-5-2014
Product:
ScreenPoint Medical develops image
analysis technology for automated reading
of mammograms and digital breast tomosynthesis.
Initially, ScreenPoint will develop and market a next
generation
system for computer aided detection in screening
mammography.
CEO: Nico Karssemeijer, Michael Brady
Headcount: 2
www.screenpoint-medical.com